Referenzen

Si, L., et al. (2020). "Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge." Value Health 23(9): 1163-1170. (Schramm W), DOI: 10.1016/j.jval.2020.04.1832, PMID: 32940234

Pobiruchin M, Zowalla R, Kurscheidt M, Schramm W. PrositNG – A Machine Learning Supported Disease Model Generation Software. Studies in Health Technology and Informatics 272:151-154. DOI: 10.3233/shti200516

Schramm W, Sailer F, Pobiruchin M, Müller A, Weissman J. The Cost-Effectiveness of the PDM-ProValue Diabetes Management Program in Germany. EASD 2019, 16.-20. September 2019, Barcelona. P820.
Sailer F, Pobiruchin M, Müller A, Weissmann J, Schramm W. Makrovaskuläre Ereignisse, Lebensqualität und Mortalität im PDM-ProValue Studienprogramm – eine vergleichende Langzeitsimulation. Diabetologie und Stoffwechsel 2019; 14(S 01): S13. DOI: 10.1055/s-0039-1688141

Schramm W. Digital Diabetes Self-Management: A Trilateral Serial. Journal of Diabetes Science and Technology(2018), DOI 10.1177/1932296818761973

Heinemann L, Daenschel W, Daenschel I, Messinger D, Schramm W, Vesper I, Weissmann J, Kulzer B: Integrated personalized diabetes management (iPDM) in patients with insulin-treated T2DM: results of the PDM-ProValue study program. Poster Presentation at the Congress of the International Diabetes Federation in Abu Dhabi 2017 DOI: 10.1177/1932296815617487

Sailer F, Hunter R, Schramm W (2017): Development of a chlamydia infection model for evaluating costs and outcomes of health interventions. In: GMS Medizinische Informatik, Biometrie und Epidemiologie 13 (1). DOI: 10.3205/mibe000173
Schramm W, Rickmann J, Sailer F. Healthy, Sick, Dead – An Education Blueprint to State Transition Disease Modelling. Studies in Health Technology and Informatics Health 2017, PMID: 28679929
Seitz P, Fendrich L, Hempe H, Rickmann J, Christophidis B, Lankes S, Reimchen H, Westers M, Baumann B, Laha A, Suleder J, Sailer F, Schramm W (2017): Validierung des PROSIT CHD Type 2 Diabetes Herzinfarktmodells. In: Diabetologie und Stoffwechsel 12 (S 01), S1-S84. DOI: 10.1055/s-0037-1601719

Pobiruchin M, Bochum S, Martens UM, Kieser M, Schramm W. A method for using real world data in breast cancer modeling. J Biomed Inform. 2016 Feb 8. pii: S1532-0464(16)00019-8. doi: 10.1016/j.jbi.2016.01.017.

Kulzer, B.; Daenschel, W.; Daenschel, I.; Siegel, E. G.; Schramm, W.; Parkin C.G.; Messinger, D.; Weissmann, J.; Djuric, Z.; Mueller, A.; Vesper, I.; Heinemann, L.: Integrated Personalized Diabetes Management (PDM): Design of the ProValue Studies: Prospective, Cluster-Randomized, Controlled, Intervention Trials for Evaluation of the Effectiveness and Benefit of PDM in Patients With Insulin-Treated Type 2 Diabetes. In: Journal of Diabetes Science and Technology (2015). DOI: 10.1177/1932296815617487

Sailer F, Pobiruchin M, Bochum S, Martens UM, Schramm W. Prediction of 5-Year Survival with Data Mining Algorithms. Studies in Health Technology and Informatics. 2015; 213:75-78. DOI: 10.3233/978-1-61499-538-8-75; PMID: 26152957

Pobiruchin M, Kieser M, Schramm W. Leveraging Markov models to compute prevalence estimates for a regional breast cancer registry. Stud Health Technol Inform. 2013;190:237-9.

Willert T, Walker J, Schramm W. [Regional analysis of drug treatment prevalence and medication of diabetes mellitus in Germany]. Dtsch Med Wochenschr. 2012 Nov;137(46):2363-8. doi: 10.1055/s-0032-1327273. Epub 2012 Nov 6. German.

Schramm W. Self-Monitoring of Blood Glucose: One STeP Forward? Journal of Diabetes Science and Technology, July 2012, Volume 6, Issue 4: pages 978–982.

Schramm W, Schöll M, Hess F. Therapy of Chronic Pain in Peripheral Diabetic Neuropathy. IQWIG pilot assessment report on the relation of benefits to costs. IQWIG Institute. (1) 1-71. 23. May 2009.

Pobiruchin M, Schramm W. [Does DMP type 2 diabetes mellitus lead to better values of HbA1c and blood pressure? An analysis regarding to published quality reports] MMW Fortschr Med 2008 Apr 10.:16-21.

Martin S, Schramm W, et al. Epidemiology of Complications and Total Treatment Costs from Diagnosis of Type 2 Diabetes in Germany (ROSSO 4). Experimental Endocrinology and Diabetes. 2007 Sep;115(8):495-501.

Neeser K, Szucs T, Bulliard JL, Bachmann G, Schramm W. Cost-effectiveness analysis of a quality-controlled mammography screening program from the swiss statutory health-care perspective: quantitative assessment of the most influential factors. Value Health. 2007 Jan-Feb;10(1):42-53.

Poster award of the Swiss Society for Radiology, June 2006.

Schramm W, Haake D, Brandt A. Die Wirtschaftlichkeit von Tiotropium bei chronisch obstruktiver Lungenerkrankung. Schweizerische Rundschau für Medizin 2005-11-16;94(46): 1803 - 1810.

Schramm W, Schoffski O, Gortz A, Liebl A. [Disease modelling in diabetes mellitus] Dtsch Med Wochenschr. 2004 Oct 22;129(43):2305-10. Review. German.

K. Neeser, U. Siebert, G. Lübben, W. Schramm: Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective. Pharmacoeconomics. 2004;22(5):321-41.

Schramm W et al., the WHO St. Vincent Declaration Nephropathy Working Group: when is the optimal time for first referral of diabetes patients to a nephrologist? Diabet Med. 2003 Aug;20(8):689-90.

Schramm W. Abbildungen und Simulationen von Krankheiten in mathematischen Modellen und ökonomische Beurteilung medizinischer Outcomes. In ArzneimForsch/DrugRes, 2002, 52, 4, p. 309-351.

Piehlmeier W, Renner R, Schramm W, Schneider A, Konig A, Gottsmann M, Hardenberg R, Von Hubbenet JE, Landgraf R.: PROSIT--a quality management system for diabetic patients with nephropathy in Germany. Diabetes Nutr Metab. 2001 Apr;14(2):110-4.

Piehlmeier W, Renner R, Schramm W, Kimmerling T, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R.: Screening of diabetic patients for microalbuminuria in primary care--The PROSIT-Project. Proteinuria Screening and Intervention. Exp Clin Endocrinol Diabetes. 1999;107(4):244-51.

Piehlmeier W, Renner R, Kimmerling T, Schramm W, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R.: Evaluation of the Micral-Test S, a qualitative immunologic patient self-test for microalbuminuria: the PROSIT project. Proteinuria Screening and Intervention. Diabet Med. 1998 Oct;15(10):883-5.

W. Schramm, M. Pobiruchin. Die PROSIT Disease Modelling Community Open Source Erkrankungsmodelle für die Kosten-Nutzen Bewertung. Horizonte (37) 2011, p. 38-40 (in press).

W. Schramm: from „educated guess“ to evidence-based decision. Management & Krankenhaus. Kolumne „Querdenker“, 03/2003.

U. Schweppe, W. Schramm. Das Richtige mit dem Richtigen tun - Risikostratifizierung als Methode des Managements in der Medizin. Managed Care 7 2002 p. 34-36.

Paolo Brunetti, Carlo Lucioni, Wendelin Schramm: Terapia combinata con Pioglitazone (Actos) nel diabete di tipo 2 in Italia: valutazione farmacoeconomica, Pharmacoeconomic Issues in Type II Diabetes (Italian edition), ADIS international, ISBN: 88 88371 12 5.

W. Schramm. Rechtsmedizin pur, Lehrbuch in Karteikarten für Studenten, Börm-Bruckmeier Verlag, ISBN 3-929785-02-1.

Online Care Card Diabetes (developed by IMIB) www.diabetes-online.ch. The "Online-Gesundheits-Pass Diabetes" is an online version of the "CareCard Diabetes", a common standard document for diabetes care in Switzerland

Swiss Seminar Public Health System, Edition TrendCare, Switzerland: Chapter “Key Figures of the Swiss Health Care System”, ISBN : 3-9521639-0-2

Swiss Seminar Public Health System, Edition TrendCare, Switzerland: Chapter “Disease Management for Diabetes mellitus” ISBN : 3-9521639-0-2

Landgraf R, Renner R, Schramm W. Diabetische Nephropathie in Deutschland – das PROSIT Projekt. Apotheker Journal 1997;19(7):12-15.